White paper on how to advance cell-based Advanced Therapies in Europe

This White paper is a summary of the discussions and exchange of experiences during the first European Interdisciplinary Summit on Cell-Based ATMPs which was held at the Billroth-Haus in Vienna, Austria, May 02 - 03, 2013. The meeting was supported by the Research Networking Programme REMEDIC (REgenerative MEDICine) funded by the European Science Foundation, and by the British Medical Research Council. Scientists in academia, members of the Alliance for Advanced Therapies (AAT) and individuals from national regulatory authorities have contributed to the Summit. Some elements of this white paper are not necessarily endorsed by all of these organisations.

The biggest challenges and hurdles that need to be overcome to improve the competitiveness of Europe in the field of cell-based Advanced Medicinal Therapy Products (ATMPs) are:

• National hurdles, harmonization

Both European and US legislative frameworks have laid down rules for “complex” cell therapies to control the testing, manufacture, marketing and use of the products. A harmonization of selected rules and requirements across individual European countries is necessary, also between EMA and FDA, so that the path of product development and associated requirements becomes clear and transparent. Concerted efforts are ongoing in this regard.

A Qualified Person should be used for all ATMP release including in the context of clinical trials as for hospital exemptions. More involvement of (hospital) pharmacists is also necessary as it appears that they are not always familiar with this new class of products.

• Hospital exemption, national and subnational differences

As the ATMP regulation builds on the Medicine Directive its scope is limited to products which are intended to be placed on the market in Member States and which are either prepared industrially or manufactured by a method involving an industrial process. An exemption from the otherwise compulsory centralized licensing procedure is made for those ATMPs that are prepared on a non-routine basis, according to specific quality standards, and used within the same Member State in a hospital under the exclusive professional responsibility of a medical practitioner. Relevant Community rules related to quality and safety are not to be undermined. This so-called ‘Hospital Exemption’ represents a baseline consensus, from which Member States are called to develop their own regimes.
The Hospital Exemption is a challenge as many interpret and implement the scope of the Hospital Exemption differently. The field needs clarity about the European rules with regard to hospital exemptions and a uniform implementation of the rules defining when treatments can be done under an Hospital Exemption.

Sufficient room for early exploratory treatments in the hospital setting is required to help the field moving forward. However, hospital exemptions should not be used for the sake of local hospitals to treat patients routinely with cell-based products, or to accumulate clinical data for a certain product in those countries that do not implement strict Hospital Exemption rules. Several countries are already quite clear and transparent in this regard, others seem to remain undecided. In the long run, efficacy and safety data need to be generated and that is only possible through rigorous clinical trials.

• **Reimbursement**

Positioning cell based treatments in daily clinical practice should be addressed early in development. Early-on incorporation of approaches allowing to define appropriate patient target groups (patient stratification) and responders to treatment (e.g. using biomarkers) is critical towards a personalized medicine approach, in particular for this new class of treatments.

Collection of patient data in an attempt to properly position the treatments in daily clinical practice is an important approach for successful reimbursement discussions in the future. This can lead to new or updated treatment algorithms, and will thus be of help for the identification of well-targeted patient groups in the context of reimbursement.

• **Knowledge on the mode of action**

Although it is clear that living cells are much more complex systems than chemical drugs, it is required to better understand their main actions and attributes responsible for the intended therapeutic effect. For example, it is often not clear whether the therapeutic efficacy of a cell-based ATMP is based on a progenitor or a non-progenitor function, or, when multiple components are being used, which of those appear fundamental for the intended activity. This understanding is expected to allow for a more ‘targeted’ optimization of the cell-based product. To address this goal, novel and multidisciplinary approaches may be needed.

Part of the mode of action is also the characterisation of the functionality of the cells/tissues derived from the cell-based product, when applicable. For instance, functional cardiomyocytes are expected for regeneration of infarcted myocardium, or functional neurons expected for regenerated spinal cord.

When using human cells in animal models, immunological reactions (rejection) of the host might impair the behaviour of the donor cells (e.g., engraftment, growth, proliferation, etc.). Therefore, the use of homologous products may be advisable if practically feasible, showing the concept to work in the species tested, and providing clarification of the mechanism. One has to take into considera-
tion particular aspects of the model which might/might not differ from those in humans. The models need to be justified, their relevance to mimic humans needs to be shown, and the aspects relevant for translation into humans also need to be defined.

**Predictive preclinical efficacy and safety testing**

As for any new medicinal product, the development and approval of cell-based medicinal products need to be based on nonclinical data supportive of the mode of action and potential therapeutic action, and on appropriate safety attributes. Due to their complexity and the human origin of most cell-based ATMPs, the existing preclinical models are sometimes irrelevant for prediction of effects in human patients, and need to be adapted on a case-based manner. While the safe use of any new cell-based product need to be predicted before entrance into human experimental or therapeutic use, the strategies for data generation and the decision on which data is needed should be planned well in advance, taking into consideration the particular aspects of each product. The use of relevant experimental models is of outstanding importance, as only those will be able to appropriately support efficacy and safety of the product. Data generated in irrelevant models is a concern, as it could give a false sense of risk or of safety that may heavily impact on the appropriate use of the product.

With regard to the safety assessment of a cell-based product, general studies on safety pharmacology, repeated dose toxicity (addressing general toxicity), reproductive toxicity, and carcinogenicity are in principle needed, similar to conventional drugs. However, the experimental strategies and study design to generate such data may need adaptation to the specific nature and potential safety concerns of such living, biological products. Data and information collected from mode of action studies may also be helpful to establish safety attributes and to design the safety studies. Since a single dose of a cell-based product may lead to a persistent or long lasting exposure, its biodistribution, persistence and potential for tumour formation need to be addressed and anticipated. The extent of biodistribution, potential for ectopic engraftment, and the persistence at intended and/or unintended sites of action will dictate the extent and the type of safety studies further needed.

It is important to keep in mind that for the development of any cell-based product the characteristics of the cell product itself will dictate the type of safety concerns associated, and those which are expected to be anticipated and tested, based on the existing knowledge about the product (cell) type. This has formed the basis for the so called "risk-based approach" called for by the Committee of Advanced Therapies of the EMA (the CAT), which has issued a guideline proposing that, for any new ATMP, risks are anticipated based on the knowledge of the product (meaning that it will be science-driven, time evolving). The design for safety and efficacy studies, nonclinical or clinical, should take these risks into consideration, in addition to the quality aspects.

As for proof-of-concept studies, the animal model used for in vivo studies needs to show relevance with regard to the human situation. While rodents are
easy to use, large animals may also be needed, depending on the product type and indication (e.g., horses or goats for cartilage repair or pigs for spinal cord injury). However, large animals are difficult to use for safety purposes, and their use is normally more common for proof-of-concept studies. Nevertheless, inclusion of safety endpoints in proof-of-concept studies whenever possible, will make those more informative, and will contribute to reduction of animal use according to the 3R policy.

While the use of homologous products might be the most helpful and meaningful for the prediction of any efficacy and/or safety concern associated to the cell-based product concept, it is usually not accepted by regulatory authorities that a human cell-based product is developed based on "conceptual" data only, without actual testing of the clinical candidate. This means that the genuine cell-based medicinal product needs also be tested, which, being of human origin, will lead to immunological reactions in animal species. Immunosuppressed animals (rodents) are mostly used to overcome this problem in safety testing. To allow for a good understanding of the animal-specific features, and in the ideal situation, it is advisable that the clinical candidate is tested in immunosuppressed animals in conjunction to the homologous product in immunocompetent animals. Inclusion of safety endpoints in the proof-of-concept study may overcome the need for separate safety studies with the homologous product. Taking these aspects into consideration is obviously a matter of careful early planning, starting with the proof-of-concept.

It is expected that a science-driven, case- and risk-based approach for development of cell-based products will improve characterization and facilitate early planning of necessary study packages for successful marketing.

• Need for innovative systems for preclinical testing

For many cell-based products it is possible to anticipate their human efficacy and safety based on the knowledge associated to the product characteristics, and the outcome of their testing (or of testing of homologous products) in animal species. However, there are cases in which animal efficacy and safety data are difficult to interpret and extrapolate to humans, e.g., for cancer immunotherapy, where efficacious products in rodents have shown highly disappointing results when entering clinical trials.

When animal models are judged as not being useful or misleading, alternative approaches are commonly considered as "rescue" options, using in vitro systems which desirably are based on human systems (cells/tissues in culture). When the preclinical development of a product is based exclusively on in vitro data, the transfer into humans for the first clinical trials is made with an extra-cautiously approach, but still cases do exist, and the unavailability of appropriate animal models should not be a reason for blocking a development plan, particularly in therapeutic areas of high need.

The advances in the field of cell-based therapies led to increased knowledge about different cell type attributes, identification markers, methodologies for
(sub)cellular access, identification, characterisation, growth, isolation, and culturing. Efforts have also been made towards achieving co-culturing cell systems, three dimensional (3D) cultures and organotypic cultures. While the field is still far from being ready for full use, an enormous research investment is being put in the creation of "humanized tissue/organ-like systems" which could be used for the testing of compounds directly in human-derived material. In case of success, those strategies, once integrated, may allow translational research concepts to move from the traditional "animal into human" path, towards "in vitro into in vivo human" path.

The need for such alternative in vitro systems, based on human cells, allowing appropriate and reliable testing of main safety aspects associated to new pharmaceuticals is paramount. For cell-based products this is even more relevant, given the specific nature and sometimes questionable relevance of the animal models being used. In an ideal situation, it is expected that systems like the "human on a chip" where multiple "organotypic constructions" are kept connected by microfluidic circulation would allow the understanding of the potential cell products to express their intended and unintended properties, covering tissue access, tissue engraftment, ectopic engraftment, cell persistence, senescence, degeneration, cell-derived products identification, etc. If appropriately collected and interpreted, data generated in these systems, based on well formulated questions (e.g., the risk based approach) might allow a careful introduction of such products in humans, with appropriate tools for cell tracking (e.g., imaging) and even cell suicidality in case of need.

Multiple initiatives in the European arena and worldwide are currently being carried out in order to put these possibilities into reality, for the sake of improved success in drug development and human health.

- **Product characterization and product potency**

Product characterization and analysis of product potency for ATMPs may be of higher complexity than for other biochemically derived biologicals but nevertheless are of high importance due to potential manufacturing process variability and the living nature of the product. Current approaches used in cell therapy product manufacturing processes often include biologically variable starting materials, and the criticality of a wide range of process steps for the quality of the final product in terms of impact on the living cells and their behaviour and ultimately product potency is often unclear. Early efforts in product characterization and development of potency assays (combined with a structured process development approach) allow fact-based evaluation on product consistency when changes and improvements are made to the manufacturing process. Conceptually this provides a type of insurance premium to enable effective continuation of the project even at times when important unexpected process outcomes are experienced or changes in reagents or to the manufacturing process become necessary: the fact base allows charting a path forward. A further important aspect of product characterization is the development of a scientific rationale for the dose to be applied to the patient.
Manufacturing with cost of goods in mind

Whereas in early stage clinical trials emphasis of many companies is exclusively on manufacturing products according to specifications and under GMP conditions, later the focus will promptly shift to scale-up and achieving acceptable cost of goods. A clear understanding of the target indication, its value range, and estimation of patient cell dosages will be required to come to an evaluation of whether the initial product platform will be able to deliver commercially acceptable costs. In most cases early attention is recommended to implement scale-up activities. From such an integrative perspective one can carefully select steps to either achieve scale-up immediately or to allow easier scale-up at a later phase. A clear path needs to be charted on how to deal with the scale-up question early on, even though a delay may be required due to lack of funds in earlier clinical phases. Investors will be keen to have an in-depth understanding on how scale up can be achieved as this is currently seen as one of the most important hurdles of commercial success for cell-based ATMPs.

Clinical trials: design and outcomes

Clinical trials are necessary to allow the assessment of the safety and efficacy of new cell-based ATMPs. It involves exploratory trials and confirmatory trials. Typically, a phase I/IIa study looking at the safety and feasibility of the treatment, with some indications of efficacy. Already in this phase, an effort should be made to identify the type of patients that are responsive to these treatments, allowing for potential patient stratification in subsequent trials.

Randomized controlled phase II studies are mandatory to assess dose finding, treatment efficacy, and safety. (Multicentre) phase III studies are needed for definitive testing before market authorization or employment as standard treatment.

After market authorization, it is suggested that the collection of postmarketing real life patient data in daily clinical practice is more useful and relevant over running many smaller, confirmatory trials in different patient subpopulations. The rationale behind this approach is to better define the right product for the right patient at the right time, information which may also be used for adaptation and fine-tuning of reimbursement criteria. All patients treated in clinical trials and in later standard treatment should be monitored for long term safety and efficacy. In the ideal situation, this long-term vigilance monitoring should include data on quality of life and treatment costs.

More adapted trial designs may be appropriate as many indications for the cell based ATMPs are for niche patients, potentially orphan drug indications.

Long-term follow up is of importance, in particular for allogeneic cell-based treatments. Development of methodologies to trace cells over time appears important, also in view of long term safety.
The following individuals contributed to this White paper:

Reinhold G. Erben, MD, DVM, Professor of Physiology and Pathophysiology, University of Veterinary Medicine, Vienna, Austria

Frank P. Luyten, MD, PhD, Professor of Rheumatology, KU Leuven, Leuven, Belgium

Gerjo J.V.M. van Osch, PhD, Professor of Connective Tissue Regeneration, Dept. of Orthopaedics & Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam, The Netherlands

Beatriz Silva-Lima, PhD, Professor of Pharmacology and Pharmacotoxicology, University of Lisbon, Lisbon, Portugal

Gustav Steinhoff, MD, Professor of Cardiac Surgery, University of Rostock, Rostock, Germany

Gudrun Tiedemann, PhD, University of Rostock, Rostock, Germany

Katarina Le Blanc, MD, PhD, Professor of Clinical Stem Cell Research, Karolinska University Hospital, Stockholm, Sweden

Wilfried Dalemans, PhD, CTO, TiGenix, Leuven, Belgium

Alexander Vos, CEO, Pharmacell, Maastricht, The Netherlands

Rob T.A. Janssen, CEO, Scalable Life Sciences, Zoetermeer, The Netherlands

Ilona Reischl, PhD, Austrian Medicines and Medical Devices Agency, BASG/AGES, Vienna, Austria